A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma
Step 1 (prestudy screening) of S1404 study is closed to accrual effective August 15, 2017, at 11:59 p.m. Pacific Time.
Step 2 (randomization) of S1404 study is closed to accrual effective November 2, 2017, at 11:59 p.m. Pacific Time.
